ARS Pharmaceuticals (SPRY) Operating Expenses (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Operating Expenses data on file, last reported at $82.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 83.45% year-over-year to $82.8 million; the trailing twelve-month figure through Mar 2026 stood at $301.4 million (up 142.69% YoY), and the FY2025 full-year result was $263.7 million, up 185.94% from the prior year.
• Operating Expenses grew to $82.8 million in Q1 2026, from $69.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $85.7 million in Q3 2025 to a low of $6.8 million in Q2 2022.
• A 5-year average of $32.0 million and a median of $18.7 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses sank 72.22% in 2022 and surged 299.82% in 2025, its largest moves.
• Tracing SPRY's Operating Expenses over 5 years: stood at $15.4 million in 2022, then tumbled by 33.78% to $10.2 million in 2023, then jumped by 285.14% to $39.4 million in 2024, then soared by 76.6% to $69.6 million in 2025, then climbed by 19.09% to $82.8 million in 2026.
• Business Quant data shows SPRY's Operating Expenses at $82.8 million in Q1 2026, $69.6 million in Q4 2025, and $85.7 million in Q3 2025.